

# Association of ABO blood type with mortality in hospitalized patients with COVID-19

## Asociación de los grupos sanguíneos ABO con la mortalidad en pacientes hospitalizados por COVID-19

Martín Uriel Vázquez-Medina<sup>1</sup>,  Eira Cerda-Reyes<sup>2</sup>,  Arcelia Carolina Barrón-Campos<sup>3</sup>,   
José Antonio Almeyda-Farfán<sup>4</sup>,  María Esther Ocharan-Hernández<sup>5</sup>,  Cruz Vargas-De-León<sup>6</sup> 

DOI: 10.19136/hs.a21n1.4516

Research article

• Received date: April 24, 2021 • Accepted date: June 7, 2021 • Published online: October 20, 2021

Corresponding Author:

Cruz Vargas-De-León. Postal address: División de Investigación, Hospital Juárez de México, Av Instituto Politécnico Nacional 5160, Alcaldía Gustavo A. Madero, CP. 07760, Ciudad de México, Mexico.  
E-mail: leoncruz82@yahoo.com.mx

### Abstract

**Objective:** To explore the relation between ABO blood group system and in-hospital mortality in Mexican patients admitted with COVID-19.

**Materials and methods:** We performed a retrospective study with 2,369 hospitalized patients with confirmed SARS-CoV-2 infection in a tertiary referral hospital, admitted between March 27 and December 10, 2020. Data were obtained from electronic health records. Adjusted and unadjusted Cox Proportional-Hazard models were performed to test the association of ABO blood groups with mortality of COVID-19 patients. The variables considered for adjustment of the models were age, sex, and main comorbidities.

**Results:** Out of all studied patients, group O was the most frequent blood type with 1999 patients (84.3%), followed by group A (11.3%), B (3.5%) and AB (0.72%). Blood group A was associated with a lower hazard of death among COVID-19 patients compared with group O (adjusted HR = 0.72, 95% IC 0.55-0.95, P = 0.02. Groups B, AB and Positive Rh were not significantly associated with the outcome.

**Conclusions:** We found evidence of a statistically significant association between ABO blood type and COVID-19 in-hospital death. Patients with blood group A may be less likely to die during hospitalization compared with group O.

**Keywords:** COVID-19; Blood Group Antigens; Mortality; Prognosis.

### Resumen

**Objetivo:** Explorar la relación entre los grupos sanguíneos del sistema ABO y la mortalidad hospitalaria en pacientes mexicanos ingresados por COVID-19.

**Materiales y métodos:** Se realizó un estudio retrospectivo con 2,369 pacientes hospitalizados con infección confirmada por SARS-CoV-2 en un hospital de tercer nivel, ingresados del 27 de marzo al 10 de diciembre del 2020, los datos fueron obtenidos del expediente clínico digital del hospital. Se realizaron modelos de Riesgos-Proporcionales de Cox ajustados y no ajustados para evaluar la asociación de los grupos sanguíneos ABO con la mortalidad hospitalaria de los pacientes COVID-19. Las variables consideradas en el modelo ajustado fueron edad, sexo y principales comorbilidades.

**Resultados:** De todos los pacientes estudiados, el grupo O fue el más frecuente con 1999 pacientes (84.3%), seguido por el grupo A (11.3%), B (3.5%) y AB (0.72%). El grupo sanguíneo A se asoció a menor riesgo de muerte entre pacientes con COVID-19 comparado con el grupo O (HR ajustado = 0.72, IC 95% 0.55-0.95, valor de P = 0.02). Los grupos B, AB y Rh positivo no se asociaron significativamente con el desenlace.

**Conclusiones:** Encontramos evidencia de una asociación estadísticamente significativa entre los grupos sanguíneos ABO y la muerte por COVID-19 en pacientes hospitalizados. El grupo A podría ser menos susceptible a morir durante la hospitalización respecto al grupo O.

**Palabras claves:** COVID-19; Antígenos de Grupos Sanguíneos; Mortalidad; Pronóstico

<sup>1</sup> Médico, Becario de la Dirección General de Calidad y Educación en Salud, Secretaría de Salud, Escuela Superior de Medicina, Instituto Politécnico Nacional. Ciudad de México, México.

<sup>2</sup> Médica Gastroenteróloga, Maestra en Ciencias, Jefa de la coordinación académica del Hospital Central Militar, Secretaria de la Defensa Nacional. Ciudad de México, México.

<sup>3</sup> Médica, Departamento de Investigación, Hospital Central Militar, Secretaria de la Defensa Nacional. Ciudad de México, México.

<sup>4</sup> Médico, Departamento de Investigación, Hospital Central Militar, Secretaria de la Defensa Nacional. Ciudad de México, México.

<sup>5</sup> Médica, Doctora en Ciencias, Coordinadora del Maestría en Ciencias de la Salud, Escuela Superior de Medicina, Instituto Politécnico Nacional. Ciudad de México, México.

<sup>6</sup> Matemático, Doctorante en Ciencias, Facultad de Matemáticas, Universidad Autónoma de Guerrero; Escuela Superior de Medicina, Instituto Politécnico Nacional; División de Investigación, Hospital Juárez de México. Ciudad de México, México.

## Introduction

The novel beta-coronavirus SARS-CoV-2 infection (COVID-19), that emerged in December 2019, has generated a global crisis. As of April 2021, over 140 million people have been infected with SARS-CoV-2, of which nearly 3 million people have died<sup>1</sup>. In Mexico over 2.3 million people have been infected and more than 216,000 deaths have been reported, being one of the countries with the highest COVID-19 death tolls worldwide, behind Brazil and The United States of America<sup>2</sup>.

Severe cases in susceptible patients have been associated with the development of a condition called “cytokine storm” in response to SARS-CoV-2 antigens<sup>3</sup>. Cytokine storm consists of a deregulated immune response with excessive production and release of interleukin (IL)-1, IL-8 and IFN- $\gamma$ , leading to hemodynamic compromise and multiple organ failure<sup>4,5</sup>. The reason why some patients are more susceptible to developing severe disease has not been fully elucidated. According to clinical and basic research, factors such as older age, being male, and comorbidities like type 2 diabetes, obesity, hypertension, asthma, chronic obstructive pulmonary disease (COPD), or cancer have been associated with more severe disease and increased mortality in patients with COVID-19<sup>6,7,8</sup>.

It is necessary to find prognosis factors for patients hospitalized with SARS-CoV-2 to identify patients with increased mortality-risk and help manage hospital occupancy more efficiently. Furthermore, the knowledge of these factors could help to understand the mechanisms that lead to severity observed in patients with common characteristics. Besides the factors mentioned above, there has been an increasing interest in the relationship between the ABO blood group system and COVID-19 severity. Several studies have shown that polymorphisms within the ABO gene are associated with different traits, including risk factors for COVID-19 mortality. For instance, variants of ABO groups have been linked to diseases like gastric cancer, myocardial infarction, type 2 diabetes, and venous thromboembolism<sup>9</sup>.

The relation between ABO groups and morbidity and mortality in viral infections has been well documented. The findings of Liao (2020) suggest that individuals with blood group O may be more susceptible to norovirus infection, although these individuals appear to be less susceptible to SARS-CoV-1 and Norwalk infection<sup>10,11</sup>. Increased susceptibility to rotavirus gastroenteritis and smallpox have been observed for blood group A and groups A and AB, respectively<sup>12</sup>. Furthermore, there is evidence suggesting an increased risk of developing severe viral illness according to an individual's blood group; for instance, group AB has been associated with 2.5 greater risk of developing severe dengue infection<sup>11</sup>.

There is enough evidence to support the hypothesis that patients with blood group A are more likely to have SARS-CoV-2 infection compared with group O. Gollineli (2020) found through a meta-analysis that COVID-19-positive individuals are more likely to have blood group A (pooled OR 1.23, 95% IC 1.09-1.4) compared with blood group O (pooled OR 0.77 95% IC 0.67-0.88). Some claims have been made about the possible explanation of this relationship, including the modulation of angiotensin-converting enzyme 2 (ACE2) expression by the ABO blood group locus and the possible cross-reactivity of SARS-CoV-2 antigens with blood group O natural anti-A and anti-B antibodies<sup>13,14</sup>.

Regarding the association of ABO blood groups with COVID-19 mortality, early reports from Wuhan found that group O was linked with a higher risk of COVID-19 severity and mortality compared with group A. In a meta-analysis by Wu (2020) including predominantly Chinese populations, no association between ABO blood groups and COVID-19 severity and mortality was found<sup>15</sup>. However, studies carried out in other countries have shown contradictory results, proposing a more complex relation between ABO blood groups and COVID-19 mortality. For example, a study from the United States with 14,112 confirmed SARS-CoV-2 patients found a decreased risk of death and intubation in patients with group A relative to group O<sup>9</sup>.

Latin-American studies of ABO blood groups and COVID-19 are scarce, based on small samples and not adjusted for other variables; thus, the relationship between COVID-19 and in-hospital mortality has not been reported in Mexican populations. The aim of this paper is to explore the association between ABO blood groups and in-hospital mortality in Mexican patients admitted with COVID-19.

## Materials and Methods

We performed a retrospective study with 2,369 hospitalized patients with confirmed SARS-CoV-2 infection in a tertiary referral hospital in Mexico City, Mexico (Central Military Hospital [CMH], from the National Secretariat of Defense [SEDENA, for its acronym in Spanish]). SARS-CoV-2 infection was confirmed using real-time reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal swab. Epidemiological data including age, sex, blood group and comorbidities were obtained from electronic health records (Digital Health System) of the CMH. We included all patients with confirmed SARS-CoV-2 infection who either died or were discharged between March 27 and December 10, 2020. ABO groups and Rh types were determined through agglutination techniques by a clinical laboratory affiliated to SEDENA when patients were first included in the Digital Health System. Patients with incomplete data were excluded.

Data are presented as mean (standard deviation [SD]) and counts (percentage) for numerical and categorical variables, respectively. Two groups were formed according to one of two outcomes: death or discharge. Categorical variables were compared using the Chi-square test or Fisher's exact test, and continuous variables were compared using an unpaired t-test. Survival curves stratified according to ABO blood group were estimated using the Kaplan-Meier method, and curves were compared using the Breslow test. A multivariate Cox proportional hazard regression was performed to identify variables independently associated with COVID-19 death during hospitalization. Hazard Ratios (HR) were estimated as a measure of effect size of the variables included in the Cox regression. We fitted the following saturated model:

$$\ln(\lambda_t) = \ln(\lambda_{0t}) + b_1(\text{Age}) + b_2(\text{Sex}) + b_3(\text{ABO})_{\text{Dummy}1} + b_4(\text{ABO})_{\text{Dummy}2} + b_5(\text{ABO})_{\text{Dummy}3} + b_6(\text{Rh}) + b_7(\text{Diabetes}) + b_8(\text{Hypertension}) + b_9(\text{Obesity}).$$

Where  $\ln(\lambda_t)$  is the natural logarithm of the hazard at time  $t$ , and  $\ln(\lambda_{0t})$  is the natural logarithm of the baseline hazard. We checked the proportional hazard assumption for categorical variables by using the graph of the  $\log(-\log(\text{survival}))$  versus survival time. We determined adjusted and unadjusted odds ratios (OR) from logistic regression models to predict COVID-19 mortality. We checked the goodness of fit of logistic models with the Hosmer-Lemeshow test. The saturated logistic model included the same variables as the saturated Cox model. P values  $<0.05$  were considered as statistically significant. All analyses were performed with IBM Statistics SPSS 21, whereas bar graphs and forest plots were elaborated in GraphPad Prism 8.4.0.

This study was approved by the research committee at the Central Military Hospital with registration number 066/2020. The present study complied with the basic principles of human research following the Helsinki Declaration of the Medical Association. The data collected was handled confidentially.

## Results


A total 2,369 patients were evaluated; 1,685 (71.1%) patients were discharged, and 684 (28.8%) patients died during hospitalization. Most patients were male 1478 (62.3%). The mean age was 53.5 years (SD 16). The most frequent comorbidities were type 2 diabetes (DM) (14.8%), hypertension (14.5%) and obesity (11.4%). Non-survivor patients were older with a mean age of 63 (SD 14.1). Most patients were male, compared with the survivor group (67% vs 60%) ( $P = 0.003$ ). The most frequent comorbidities among non-survivor patients were hypertension (22.1%), DM (14.8%), and obesity (17.3%). Of the total population, 574 (24.2%) were active military personnel.

Group O was the most prevalent group in 1,999 patients (84.3%); the distribution of ABO groups is shown in Figure 1. Distribution of ABO blood groups in discharged and deceased patients are presented in Figure 2. A total 2,330 (98.3%) patients were Rh-positive among the total population. Epidemiological features of these groups are listed in Table 1. Compared with discharged patients, the percentage of blood group O was significantly higher in patients who died (83.3% vs 87%) ( $P < 0.001$ ), whereas the percentage of patients with blood group A was significantly lower (12.3% vs 8.88%) ( $P < 0.001$ ). Kaplan-Meier curves are shown in Figure 3; survival for different ABO blood groups were significantly different ( $P = 0.02$ ).

Adjusted and unadjusted Cox model analyses are presented in Table 1. Unadjusted and adjusted odds ratios of risk factors for COVID-19 mortality are shown in Table 2. A Forest Plot of the hazard ratios of death for ABO blood groups is presented in Figure 4.


In summary, blood group A had a significant lower risk of death compared with group O (adjusted HR = 0.72, 95% IC 0.55-0.95,  $P = 0.02$ ). Groups B, AB and Rh-positive were not significantly associated with the outcome. Moreover, type 2 diabetes (adjusted HR 1.54, 95% IC 1.27-1.88,  $P < 0.001$ ) and obesity (adjusted HR 1.95 95% IC 1.6-2.39  $P < 0.001$ ) were statistically significantly associated with an increased risk of death by COVID-19. Hypertension showed not statistical significance with respect to mortality in the adjusted model (adjusted HR 0.87, 95% IC 0.7-1.06  $P < 0.8$ ), despite being associated with mortality in the unadjusted model (unadjusted HR 1.76 1.95% IC 1.47-2.11  $P < 0.001$ ).

**Figure 1.** Overall ABO blood group distribution in 2,369 hospitalized patients with COVID-19.




Source: Own data

**Figure 2.** Comparison of ABO blood group distribution between hospitalized patients with COVID-19 who died or were discharged.



**Figure 3.** Kaplan-Meier survival curves for 2,369 hospitalized patients with COVID-19 stratified by ABO blood group (Breslow test P = 0.02).



Source: Own data

Source: Own data

**Table 1.** Analysis of risk factors associated with mortality in patients with COVID-19.

Characteristic	Outcome			Cox proportional-hazards models			
	Death n = 686	Discharged n = 1683	P-value	Unadjusted HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
Age	83 (14.1)*	50 (15.2)*	<0.001	1.045 (1.04 - 1.05)	<0.001	1.046 (1.04 - 1.05)	<0.001
Sex (Male)	460 (87%)**	1 018 (80.4%)**	0.003	1.19 (1.01 - 1.39)	0.03	1.4 (1.19 - 1.65)	<0.001
Blood type O	597 (87%)	1402 (83.3%)	0.097***	1 Reference		1 Reference	
Blood type A	61 (8.8%)	208 (12.3%)		0.71 (0.54 - 0.92)	0.01	0.72 (0.55 - 0.95)	0.02
Blood type B	24 (3.5%)	80 (3.5%)		0.92 (0.61 - 1.32)	0.7	0.99 (0.65 - 1.49)	0.9
Blood type AB	4 (0.5%)	13 (0.7%)		0.95 (0.35 - 2.54)	0.9	0.88 (0.33 - 2.37)	0.8
Rh	677 (98.8%)	1 653 (98.2%)	0.4	0.78 (0.4 - 1.5)	0.4	0.63 (0.32 - 1.23)	0.1
Diabetes type 2	166 (24.2%)	185 (10.9%)	<0.001	2.06 (1.73 - 2.46)	<0.001	1.54 (1.27 - 1.88)	<0.001
Hypertension	152 (22.1%)	193 (11.4%)	<0.001	1.76 (1.47 - 2.11)	<0.001	0.87 (0.7 - 1.06)	0.8
Obesity	121 (17.6%)	150 (8.9%)	<0.001	1.77 (1.45 - 2.16)	<0.001	1.95 (1.6 - 2.39)	<0.001

\* Mean (SD); \*\* n, (%); SD, Standard Deviation; HR, Hazard Ratio; CI, Confidence Interval; \*\*\*Fisher's exact test

Source: Own data


**Table 2.** Odds ratios (OR) from logistic regression models to predict COVID-19 mortality.

Characteristic	Logistic models			
	Unadjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
Age (>59 years)	3.961 (3.29 - 4.77)	<0.001	4.014 (3.29 - 4.89)	<0.001
Sex (Male)	1.33 (1.10 - 1.60)	0.003	1.65 (1.35 - 2.03)	<0.001
Blood type O	1 Reference		1 Reference	
Blood type A	0.69 (0.51 - 0.93)	0.015	0.68 (0.49 - 0.95)	0.02
Blood type B	0.94 (0.58 - 1.52)	0.8	1.02 (0.60 - 1.71)	0.95
Blood type AB	0.72 (0.24 - 2.23)	0.57	0.54 (0.16 - 1.82)	0.32
Rh	0.73 (0.35 - 1.55)	0.41	0.61 (0.27 - 1.37)	0.23
Diabetes type 2	2.59 (2.05 - 3.26)	<0.001	1.97 (1.50 - 2.60)	<0.001
Hypertension	2.20 (1.74 - 2.78)	<0.001	1.08 (0.82 - 1.44)	0.58
Obesity	2.19 (1.69 - 2.83)	<0.001	2.41 (1.82 - 3.20)	<0.001

OR, Odds Ratio; CI, Confidence Interval

Source: Own data

**Figure 4.** Forest Plot showing Hazard Ratios of death for ABO blood types during the period between March 23 and December 10, 2020. 1. Unadjusted Cox Proportional-Hazard model. 2. Adjusted Cox Proportional-Hazard model, considering age, sex, type 2 diabetes, hypertension, and obesity.



Source: Own data

## Discussion

Mexico has been one of the most affected countries by COVID-19 worldwide as reflected by the death-toll in hospitalized patients. Therefore, identifying in-patient mortality-associated factors in the Mexican population is of utter importance<sup>1</sup>. The main results of this study include a statistically significant difference in mortality of COVID-19 patients according to their ABO blood type. Additionally, obesity was the comorbidity with the greatest impact in mortality of the studied population.

In the Central Military Hospital, the three most frequent comorbidities in non-survivors were the same as those reported in other studies of Mexican patients, however, their order of prevalence differed<sup>16,17</sup>. Vera-Zertuche (2021) reported that the three main comorbidities present in non-survivors were hypertension (43%), type 2 diabetes (38%), and obesity (30.5%); the lower prevalence of these comorbidities in our study could be attributable to a lower risk of metabolic diseases in 33% of our population who were active military personnel with an active lifestyle due to their military endeavors<sup>18</sup>. Thus, comorbidities do not fully explain the high risk of developing severe COVID-19 and death in apparently healthy patients in whom other characteristics could be responsible for favoring disease progression and death.

Several reports have identified genetic mechanisms which are strongly heritable that increase susceptibility to severe SARS-CoV-2 infection. These mechanisms are related to innate antiviral defenses and host inflammatory lung response<sup>19</sup>. Innate antiviral defense activation is important early during disease and signaling by interferons is essential for response to viral infection. Damage in the interferon receptor subunit 2 (IFNAR2) is associated with severe COVID-19<sup>19,20</sup>. Furthermore, decreased expression of the

interferon-inducible oligoadenylate synthase gene cluster (OAS) has been implicated in susceptibility to SARS-CoV-2<sup>21</sup>. The mechanisms involved in lung inflammation are linked to the late complications of the disease. One of the most important mechanisms involved is the over-expression of CC-chemokine-receptor 2, which promotes chemotaxis of monocytes-macrophages to sites of inflammation, thereby increasing damage due to the inflammatory response<sup>22</sup>.

After multivariate adjustment, obesity was the comorbidity with the highest impact on mortality in our study; type 2 diabetes, older age, and male gender were also associated with mortality, similar to other observational studies<sup>19,23,24</sup>. Mechanisms of susceptibility to COVID-19 in obesity have not been fully characterized; preliminary studies mention the role of chronic inflammation, metabolic dysfunction, deficiency of vitamin D, gut microbiota dysbiosis and over-expression of ACE2 protein as factors that could explain increased mortality<sup>25</sup>. Regarding patients with diabetes, impaired phagocyte cell capabilities, over-expression of Furin and ACE-2 receptor and altered function of T-cells could be involved<sup>26</sup>. The worst prognosis reported in elderly patients could be due to the many chronic diseases seen in this population and the dysregulation of lymphoid organs; it has also been found that DPP4 enzymatic expression is higher in elderly people. SARS-CoV-2 uses DPP4 to enter cells and its upregulation has been reported in patients with severe disease<sup>27</sup>. The lower risk of developing severe COVID-19 women could be attributed to their ability to mount more robust innate antiviral responses than males<sup>28</sup>.

We found evidence that blood group A was associated with a lower hazard of death among COVID-19 patients (Unadjusted HR = 0.71 IC 0.54-0.92), whilst a higher risk of death was found for group O. Moreover, the association between mortality and blood group in the univariate analysis was quite

similar when the Cox model was adjusted for the main risk factors that influence COVID-19 mortality in the Mexican<sup>16-18</sup>. In the adjusted model, blood group A kept the lower hazard of death compared with group O (Adjusted HR = 0.72, 95% IC 0.55-0.95). Groups B and AB do not appear to be associated with the studied clinical outcomes. In both the univariate and multivariate analyses, the measures of effect size OR and HR showed the same associations between risk factors and COVID-19 mortality. Interestingly, we obtained very similar adjusted HR and adjusted OR estimates for risk factors when a subgroup analysis was performed excluding active military personnel (Data not shown).

There are only few studies comparable to ours performed in hospitalized populations. Yet, our findings match those of studies carried in Saudi Arabia and Egypt<sup>29</sup> (Group O was associated with higher intubation rates compared with group A) and USA (patients with blood Group A had a lower risk of intubation and death compared with groups AB and O)<sup>9</sup>. Nonetheless, our results contradict those of studies carried out in France, Iraq, and Canada in which group A conferred a higher mortality risk, and those from Denmark and China in which no association was found between ABO groups and death<sup>29,15</sup>.

Severe and critical COVID-19 have been associated with a pathological state characterized by rapid and prolonged systemic elevation of cytokines and chemokines named "cytokine storm". Several studies have linked the cytokine storm with tissue injury, multiple organ failure and death<sup>30</sup>. The increased mortality risk of patients with blood type O observed in our study could be explained by the evidence that suggests that these patients have increased IL-6 and IL-10 levels compared with patients with other blood types. High levels of IL-6 have been reported in patients infected with *Helicobacter pylori* and a genome-wide association study reported increased susceptibility of group O cells to release more IL-10<sup>31</sup>. Moreover, another study reported that patients with blood group O had higher levels of IL-10 in response to acute coronary syndrome<sup>32</sup>. Even though IL-10 was thought to suppress inflammation, new evidence suggests that early dramatic elevation of IL-10 may play a pathological role in COVID-19<sup>33</sup>.

The controversy across reports could be explained by genetic variations among patients with the same blood type and the traits associated with different blood types which could be developed only under certain lifestyle circumstances such as hypertension in people with blood group O<sup>34</sup>. Furthermore, the relationship between ABO blood groups and mortality could be more complex, and certain lifestyles or genetic conditions in distinct populations could synergize with certain blood groups to favor a deregulated immune system with greater risk of developing a life-threatening COVID-19 scenario.

Limitations of this study are those inherent to retrospective studies. Secondly, the population consisted only of Mexicans receiving medical care in Mexico City; therefore, our results cannot be generalized to other populations. Thirdly, we had insufficient data to estimate indicators of COVID-19 severity rates.

In conclusion, we found evidence of a significant association between ABO blood type and COVID-19 in-patient death. Blood group A may be less likely to experience death during hospitalization compared with group O. There were no significant associations between blood groups AB and B with the risk of COVID-19 death.

## Conflicts of Interest

The authors declare no conflicts of interest

## Authors contribution

Conceptualization and design, C.V.DL. and M.U.V.M; Methodology, C.V.DL. and M.U.V.M; Data acquisition and software, E.C.R, C.A.B.C. and J.A.A.F.; Data curation, analysis and interpretation, M.U.V.M, C.V.DL. and E.C.R.; Principal investigator, C.V.DL.; Investigation, M.U.V.M, C.A.B.C. and J.A.A.F.; Manuscript writing-Preparation of original draft, M.U.V.M; Writing, review and editing of manuscript, C.V.DL., M.U.V.M., E.C.R. and M.E.O.H.; Visualization, C.V.DL. and M.E.O.H.; Supervision, C.V.DL. and E.C.R.; Acquisition of funds, Not applicable

## Acknowledgments

We express our gratitude to all the staff of the Central Military Hospital - SEDENA for their work during the COVID-19 health contingency. The authors are grateful to Dr. Julian Torres Vázquez for his logistical support during the study.

## References

1. COVID-19 United States Cases by County - Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2021 Feb 20]. Available from: <https://coronavirus.jhu.edu/us-map>
2. Mortality Analyses - Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2021 Apr 29]. Available from: <https://coronavirus.jhu.edu/data/mortality>
3. Ruscitti P, Berardicurti O, Iagnocco A, et al. Cytokine storm syndrome in severe COVID-19. *Autoimmun Rev*. 2020;19(7):102562. Available from <https://doi.org/10.1016/j.autrev.2020.102562>

4. Ombrello M, Schulert G. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome? *Transl Res.* 2021; S1931-5244(21)00052-9 Available from: <https://doi.org/10.1016/j.trsl.2021.03.002>
5. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health.* 2020 ;13(12):1833-1839. Available from: <https://doi.org/10.1016/j.jiph.2020.07.014>
6. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clin Proc.* 2020 ;95(10):2189-2203. Available from: <https://doi.org/10.1016/j.mayocp.2020.07.024>
7. Mueller A, McNamara M, Sinclair D. Why does COVID-19 disproportionately affect older people? *Aging (Albany NY).* 2020 ;12(10):9959-9981. Available from: <https://doi.org/10.18632/aging.103344>
8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020 Apr 30;382(18):1708–20. Available from: <https://www.nejm.org/doi/10.1056/NEJMoa2002032>
9. Zietz M, Zucker J, Tatonetti N. Associations between blood type and COVID-19 infection, intubation, and death. *Nat Commun.* 2020 Dec 1;11(1):1–6. Available from: <https://doi.org/10.1038/s41467-020-19623-x>
10. Liao Y, Que L, Gao J, et al. ABO blood group-associated susceptibility to norovirus infection: A systematic review and meta-analysis. *Infect Genet Evol.* 2020 Jul ; 81:104245. Available from: <https://doi.org/10.1016/j.meegid.2020.104245>
11. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. *Blood Transfus.* 2021 May 12. Available from: <https://doi.org/10.2450/2021.0049-21>
12. Garratty G. Relationship of blood groups to disease: do blood group antigens have a biological role? *Rev Med Inst Mex Seguro Soc.* 2005;43(Suppl: 1):113-121. Available from: <https://www.medigraphic.com/pdfs/imss/im-2005/ims051ab.pdf>
13. Golinelli D, Boetto E, Maietti E, The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. *PLoS One.* 2020 Sep 18;15(9): e0239508. Available from: <https://doi.org/10.1371/journal.pone.0239508>
14. Zhang Y, Garner R, Salehi S, La Rocca M, Duncan D. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. *Ann Hematol.* 2021 May;100(5):1123-1132. Available from: <https://doi.org/10.1007/s00277-021-04489-w>
15. Wu B, Gu D, Yu J, Yang J, Shen W. Association between ABO blood groups and COVID-19 infection, severity, and demise: A systematic review and meta-analysis. *Infect Genet Evol.* 2020 Oct;84:104485. Available from: <https://doi.org/10.1016/j.meegid.2020.104485>
16. Nájera H, Ortega-Ávila A. Health and Institutional Risk Factors of COVID-19 Mortality in Mexico, 2020. *Am J Prev Med.* 2021; 60(4):471–7. Available from: <https://doi.org/10.1016/j.amepre.2020.10.015>
17. Escobedo-de-la-Peña J, Rascón-Pacheco R, Ascencio-Montiel I, et al. Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients With COVID-19 in Mexico. *Arch Med Res.* 2020; S0188-4409(20)32243-8 Available from: <https://doi.org/10.1016/j.arcmed.2020.12.002>
18. Vera-Zertuche J, Mancilla-Galindo J, Tlalpa-Prisco M, et al. Obesity is a strong independent risk factor for short-term mortality and adverse outcomes in Mexican patients with COVID-19: A national observational study. *Epidemiology and Infection.* 2021; 1-45. Available from: <https://doi.org/10.1017/S0950268821001023>
19. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. *Nature.* 2021 ;591(7848):92-98. Available from: <https://doi.org/10.1038/s41586-020-03065-y>
20. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020 ;370(6515): eabd4570. Available from: <https://www.doi.org/10.1126/science.abd4570>
21. He J, Feng D, de Vlas S, et al. Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. *BMC Infect Dis.* 2006; 6:106. Available from: <https://doi.org/10.1186/1471-2334-6-106>
22. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. *JCI Insight.* 2020;5(13): e139834. Available from: <https://www.doi.org/10.1172/jci.insight.139834>

23. Gérard C, Maggipinto G, Minon J. COVID-19 and ABO blood group: another viewpoint. *Br J Haematol.* 2020 ;190(2): e93–4. Available from: <https://doi.org/10.1111/bjh.16884>
24. Hoiland R, Fergusson N, Mitra A, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. *Blood Adv.* 2020 ;4(20):4981–9. Available from: <https://doi.org/10.1182/bloodadvances.2020002623>
25. Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, et al. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones. *Aten Primaria.* 2020 ;52(7):496-500 Available from: <https://doi.org/10.1016/j.aprim.2020.05.003>
26. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-1069. Available from: <https://www.doi.org/10.1001/jama.2020.1585>
27. Bajaj V, Gadi N, Spihlman A, et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? *Front Physiol.* 2021; 11:571416. Available from: <https://doi.org/10.3389/fphys.2020.571416>
28. Pradhan A, Olsson P. Sex differences in severity and mortality from COVID-19: are males more vulnerable? *Biol Sex Differ.* 2020 Sep 18;11(1):53. Available from: <https://doi.org/10.1186/s13293-020-00330-7>
29. El-Shitany N, El-Hamamsy M, Alahmadi A, et al. The Impact of ABO Blood Grouping on COVID-19 Vulnerability and Seriousness: A Retrospective Cross-Sectional Controlled Study among the Arab Community. *Int. J. Environ. Res Public Health.* 2021 ;18(1):276. Available from: <https://doi.org/10.3390/ijerph18010276>
30. Tay M, Poh C, Rénia L, et al. The trinity of COVID-19: immunity, inflammation, and intervention. *Nat Rev Immunol.* 2020 ;20(6):363–74. Available from: <https://doi.org/10.1038/s41577-020-0311-8>
31. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020 ;9(1):1123–30. Available from: <https://doi.org/10.1080/22221751.2020.1770129>
32. Johansson Å, Alfredsson J, Eriksson, et al. Genome-wide association study identifies that the ABO blood group system influences interleukin-10 levels and the risk of clinical events in patients with acute coronary syndrome. *PLoS ONE.* 2015 ;10(11): e0142518. Available from: <https://doi.org/10.1371/journal.pone.0142518>
33. Lu L, Zhang H, Dauphars D, et al. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. *Trends Immunol.* 2021 ;42(1):3-5. Available from: <https://doi.org/10.1016/j.it.2020.10.012>
34. Naitza S, Porcu E, Steri M, et al. A genome-wide association scan on the levels of markers of inflammation in sardinians reveals associations that underpin its complex regulation. *PLoS Genet.* 2012 ;8(1). Available from: <https://doi.org/10.1371/journal.pgen.1002480>